BTIG Reiterates Buy Rating on Oruka Therapeutics, Keeps $151 Target
BTIG reiterated its Buy rating and $151 price target on Oruka Therapeutics. The target implies 109.9% upside from the stock’s Oct. 16 close of $71.93.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.